Choline fenofibrate

Drug Profile

Choline fenofibrate

Alternative Names: ABT-335; Fenofibric acid; HEXA/ABT335; SLV 348; SLV348/ABT335; TriLipix

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Solvay
  • Developer AbbVie
  • Class Antihyperlipidaemics; Fibric acid derivatives; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipidaemia
  • No development reported Diabetic macular oedema

Most Recent Events

  • 12 Oct 2015 No recent reports on development identified - Phase-III for Hyperlipidaemia (Combination therapy) in Puerto Rico (PO)
  • 15 Jul 2013 Generic equivalent launched in USA
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top